MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.brs.2022.10.012

Медицинская библиотека · Brain stimulation · 2022

Assessment of safety and feasibility of non-invasive vagus nerve stimulation for treatment of acute stroke.

Arsava Ethem Murat, Topcuoglu Mehmet Akif, Ay Ilknur, Ozdemir Atilla Ozcan, Gungor Ibrahim Levent, Togay Isikay Canan, Nazliel Bijen, Kozak Hasan Huseyin, Ozturk Serefnur, Yilmaz İbrahim Arda, Dora Babur, Ay Hakan, TR-VENUS investigators

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Non-invasive vagus nerve stimulation (nVNS) using a hand-held stimulator placed on the neck is an FDA-approved treatment for primary headache disorders. The safety of nVNS is unknown in stroke patients.

OBJECTIVE

To assess the safety and feasibility of nVNS for the acute treatment of stroke.

METHODS

TR-VENUS (clinicaltrials.gov identifier NCT03733431) was a randomized, sham-controlled, open-label, multicenter trial conducted in patients with acute ischemic stroke (IS) or intracerebral hemorrhage (ICH). Patients were randomly assigned to standard-dose nVNS, high-dose nVNS, or sham stimulation. The primary endpoint was a composite safety outcome defined as bradycardia or reduction in mean arterial blood pressure during treatment or progression of neurological or death within 24 h of treatment. The feasibility endpoints were the proportion of eligible subjects receiving nVNS within 6 h of symptom onset and the proportion completing all pre-specified treatment doses. Efficacy assessments included infarct growth from baseline to 24 h after treatment.

RESULTS

Sixty-nine patients (61 IS, 8 ICH) completed the study. The composite safety outcome was achieved in 32.0% in sham and 47.7% in nVNS group (p = 0.203). Treatment was initiated in all but two randomized patients. All dosed subjects received 100% of prespecified stimulations. A non-significant reduction in infarct growth was observed in the high-dose nVNS group (184.2% in sham vs. 63.3% in high-dose nVNS; p = 0.109).

CONCLUSIONS

The results of this study suggest that nVNS may be safe and feasible in the setting of acute stroke. These findings support further development of nVNS as a potential treatment for acute ischemic stroke.

Для цитирования: Arsava Ethem Murat, Topcuoglu Mehmet Akif, Ay Ilknur, Ozdemir Atilla Ozcan, Gungor Ibrahim Levent, Togay Isikay Canan, Nazliel Bijen, Kozak Hasan Huseyin, Ozturk Serefnur, Yilmaz İbrahim Arda, Dora Babur, Ay Hakan, TR-VENUS investigators. Assessment of safety and feasibility of non-invasive vagus nerve stimulation for treatment of acute stroke.. Brain stimulation. 2022. DOI: 10.1016/j.brs.2022.10.012.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.